Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

作者：Yasmin Abaza, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Elihu H. Estey, Gautam Borthakur, Elias Jabbour, Stefan Faderl, Susan O’Brien, William G. Wierda, Sherry Pierce, Mark Brandt, Deborah McCue, Rajyalakshmi Luthra, Keyur P. Patel, Steven M. Kornblau, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Nitin Jain, Srđan Verstovšek, Alessandra Ferrajoli, Michael Andreeff, Marina Konopleva, Zeev Estrov, Maria Cielo Foudray, David McCue, Jörge E. Cortes, Farhad Ravandi · 发表于：Blood · 年份：2016 · DOI：10.1182/blood-2016-09-736686 · 被引用次数：299 · 研究领域：Retinoids in leukemia and cellular processes、Antioxidant Activity and Oxidative Stress、Acute Myeloid Leukemia Research

/L), as well as low-risk patients who experienced leukocytosis during induction. Once in complete remission, patients received 4 cycles of ATRA plus ATO consolidation. One hundred eighty-seven patients, including 54 with high-risk and 133 with low-risk disease, have been treated. The complete remission rate was 96% (52 of 54 in high-risk and 127 of 133 in low-risk patients). Induction mortality was 4%, with only 7 relapses. Among low-risk patients, 60 patients (45%) required either GO or idarubicin for leukocytosis. Median duration of follow-up was 47.6 months. The 5-year event-free, disease-free, and overall survival rates are 85%, 96%, and 88%, respectively. Late hematological relapses beyond 1 year occurred in 3 patients. Fourteen deaths occurred beyond 1 year; 12 were related to other causes. This study confirms the durability of responses with this regimen.